Skip to content
Screener

Common Stock at other companies

Amgen logo
AmgenAMGN
2.8B0.0%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$20K+25.0%
Vera Therapeutics logo
Vera TherapeuticsVERA
$72K+12.5%
PVL
Palvella TherapeuticsPVLA
$14K+27.3%
Regenxbio logo
RegenxbioRGNX
$5K0.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$6K0.0%

Other financials

Income statement

See full
Revenue$284.0K+279%
Operating income-$126.3M-18.3%
Net income-$127.1M-26.2%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$165.0M+40.6%
Total debt$114.4M+395%
Total equity$662.1M+28.5%
Total assets$1.1B+88.4%

Cash flow

See full
Operating cash flow-$105.3M-39.7%
CapEx$1.3M+3,010%
Free cash flow-$106.6M-41.4%

Valuation

See full
Market cap$2.55B+81.7%
Enterprise value$2.5B+90.9%
P/S35.9×-4,565×

Profitability

See full
Gross margin36.3%
Operating margin-569.7%-284pp
Net margin-544.1%-271pp
FCF margin-471%-235pp

Returns & leverage

See full
Return on equity-65.7%-0.1pp
Debt / equity0.2×+0.1×
Current ratio16.9×+5.9×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:31 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001590750-26-000018
Line itemJune 30,2026December 31,2025
Stockholders’ equity:
Preferred stock, series A non-voting convertible preferred stock, $0.01 par value; 435,000 shares authorized; 133,191 and 134,864 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively60,43261,188
Preferred stock, series B non-voting convertible preferred stock, $0.01 par value; 500,000 shares authorized; 48,463 and 79,620 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively37,59270,868
Common stock, $0.01 par value; 200,000,000 shares authorized; 113,238,218 and 101,826,500 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1,1321,018
Additional paid-in capital2,134,5721,927,104
Accumulated other comprehensive income (loss)(1,153)447
Accumulated deficit(1,570,478)(1,338,458)
Total stockholders’ equity662,097722,167

Item 1. Financial Statements (Unaudited)

FAQ

What is Viridian Therapeutics, Inc.'s common stock?
Viridian Therapeutics, Inc. (VRDN) reported common stock of 200M in Q2 2026.
How has Viridian Therapeutics, Inc.'s common stock changed year-over-year?
Viridian Therapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from 200M to 200M.
What is the long-term trend for Viridian Therapeutics, Inc.'s common stock?
Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s common stock has grown at a 443.9% compound annual growth rate (CAGR), from 42K to 200M.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Viridian Therapeutics, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude